Purpose: High initial serum concentrations increase the risk of cutaneous adverse reactions. Genetic variants of the main metabolizing isoenzyme, uridine diphosphate glucuronosyltransferase (UGT) 1A4 influence the elimination of lamotrigine (LTG). Our aim was to investigate the potential association between the two best studied variants, *2 (P24T) and *3 (L48V), and the occurrence non-bullous skin reactions from LTG. Method: The study included 29 patients of Caucasian ethnicity with a history of non-bullous skin reactions from LTG. 184 subjects tolerant to LTG for at least three months were used as controls. UGT1A4 genotyping was performed in all patients and controls by sequencing of the first part of exon 1. Six controls were excluded due to rare genetic variants. Results: Two of 29 subjects (7%) with rash from LTG were heterozygous for UGT1A4 *2, compared to 23 of 178 (13%) tolerant controls (p = 0.54). Four of 29 subjects (14%) with rash from LTG were heterozygous for UGT1A4 *3 compared to 25 of 178 (14%) tolerant controls (p = 0.97). Conclusion: It is unlikely that heterozygosity of the UGT1A4 genetic variants *2(P24T) or *3(L48V) influences the risk of non-bullous skin reactions in patients treated with LTG.
Introduction
Lamotrigine (LTG) is a widely used antiepileptic drug (AED) which is also effective in bipolar disorder [1] . Its side effect profile is favorable regarding its target organ, the brain. However, the skin may be affected by adverse reactions that are of notable concern and limit its use considerably. Up to 8-10% of patients treated with LTG develop cutaneous adverse reactions (cADRs) within the first eight weeks of treatment, usually requiring discontinuation of the drug [2] . Mild maculopapular exanthema (MPE) is the most common type, but the hypersensitivity syndrome (HSS) with fever and affection of other organs sometimes develops [3, 2] . Serious, bullous reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis) occur in approximately 0.1% [3] . High initial doses and rapid titration schedules increase the risk of cADRs. Valproate co-medication inhibits the main metabolizing isoenzyme, uridine diphosphate glucuronosyltransferase (UGT) 1A4. This considerably raises LTG serum concentrations and enhances the occurrence of cADRs [3] .
It has been suggested that certain pharmacogenetic polymorphisms in metabolic pathways of other aromatic AEDs may facilitate development of cADRs by slowing down their elimination or forming toxic intermediates [4, 5, 6] .
The gene that encodes UGT1A4 occurs in numerous variants. Best studied are *2 (P24T; c.70C>A; rs6755571) and *3 (L48V; c.142T>G; rs2011425), with allele frequencies of 6.3% and 7.6% in Mid Norway, respectively. Clinical studies in the same population showed that the *2 (P24T) variant is associated with a trend to higher LTG serum concentrations, whereas the *3 (L48V) variant is associated with significantly lower serum concentrations, as compared to wild type (wt) [7] .
The aim of this study was to investigate the potential association between these genetic variants of UGT1A4 and the occurrence of cADRs from LTG.
Methods
Altogether 29 patients of Caucasian ethnicity from Mid Norway with a history of cADR from LTG were enrolled. A LTG-induced cADR was defined as a diffuse rash leading to discontinuation of the drug within three months after initiation of therapy, having no other obvious cause than LTG. Skin reactions with uncertain relation to AEDs, atypical rashes, circumscribed eruptions and those which could have been caused by other drugs, infections or other skin disorders, were carefully excluded. Classification of cADRs was performed according to the phenotype standardization for immune-mediated drug-induced skin injury [8] . The cADR diagnoses were based on documentation in the medical records. Telephone interviews were performed if written documentation was considered insufficient.
A total of 184 Caucasian controls were also included; all had been exposed to LTG for at least three months without any sign of cADRs.
All rash patients and controls were genotyped. Genotyping was performed by sequencing the first part of exon 1 of UGT1A4 covering the two SNPs *2(P24T) and *3(L48V) as described by Reimers et al. [7] . The reference sequence for UGT1A4 was NM_007120.2.
Statistical analyses were performed using SPSS version 21.0. Groups were compared using a Chi-square test for categorical data. When Chi-square test included expected frequency values <5%, Fisher's exact test (two-sided) was used to calculate p-values. A pvalue 0.05 was considered statistically significant.
The study was approved by the Regional Committee for Medical and Health Research Ethics.
Results
Of 29 patients with non-bullous cARDs from LTG, 26 (90%) had MPE, whereas 3 (10%) developed HSS. There was no significant difference in the demographic characteristics between cARD subjects and controls. Among patients with rash, 22 were females (76%) and 7 were males (24%) (mean age: 29 years; range 6-69). The control group consisted of 116 females (63%) and 68 males (37%) (mean age: 29 years; range: 1-73).
Two of 29 subjects (7%) with LTG-induced cADRs were heterozygous for UGT1A4 *2(P24T), as compared to 23 of 178 (13%) tolerant controls (p = 0.54) with the same genotype. Four of 29 subjects (14%) with LTG-induced cADRs were heterozygous for UGT1A4 *3(L48V), as compared to 25 of 178 (14%) tolerant controls (Table 1 ). There was no significant difference in the frequency of these polymorphisms between subjects with cADRs and controls.
All patients with LTG-induced cARDs were either wt/wt, wt/*2 (P24T) or wt/*3(L48V). Among the controls, 178 were either wt/wt, wt/*2(P24T) or wt/*3(L48V), whereas the remaining six had other genotypes [one had *2(P24T)/*3(L48V), one was homozygous for *2 (P24T) and the others were single cases of either *3(L48V)/c.42A>G (T14T), c.107C>T (T36I)/c.119C>A (P40H), wt/c.42A>G (T14T), or wt/ c.54C>T (L18L)]. These variants were excluded from the frequency analyses due to their low number.
Discussion
This study suggests that neither of the two heterozygous UGT1A4 genotypes *2(P24T) or *3(L48V) tends to accumulate in patients with non-bullous cADRs from LTG. It is well known that initial high serum concentrations of LTG increase the risk of cADRs [3] . In this study, it was not possible to compare serum concentrations in patients with cADRs and controls, since cARDs usually occur during the early dose titration of LTG, prior to any therapeutic drug monitoring.
Previous clinical studies are discordant as to the effect of the *3 (L48V) polymorphism on the serum concentrations of LTG. A recent study from Mid-Norway [7] , as well as a Turkish study [9] , suggested lower LTG levels in subjects carrying the *3(L48V) polymorphism, whereas a Chinese study showed higher values [10] . Thus, the lacking positive association of cADRs and the *3 (L48V) variant was anticipated in the present study, as lower LTG serum concentrations rather would be expected to be a protective factor. Nevertheless, the possibility of an increased formation of reactive cADR-inducing intermediates by an enhanced metabolism of LTG had to be considered. Consistent with our findings, a small Korean study of 10 patients with cADRs related to LTG, including urticaria and transient rashes allowing treatment to continue, also found no correlation between the *3(L48V) polymorphism and cADRs [11] .
The 2*(P24T) variant of UGT1A4 is virtually absent in various Asian populations [10] . In the Norwegian study it has been associated with a trend toward slightly higher LTG serum concentrations [7] . This polymorphism has previously not been studied in relation to cADRs. Unexpectedly, we found a rather low number of non-bullous cADRs among patients with this genetic variant.
Chang et al. [10] identified two patients with the UGT1A4 127delA genotype. Both had extremely high blood levels of LTG; one had to discontinue treatment with LTG due to a cARD (unspecified type). None of our subjects had this particular UTG1A4 variant.
The findings of this study need confirmation in a larger number of patients with LTG-induced cADRs. Moreover, uncertainty of causality is a potential bias in studies of mild cADRs. However, as this was a single-center study, documentation of all skin reactions could be retrieved from the medical records and they were confirmed by the patients at inclusion. Furthermore, we cannot exclude that polymorphisms outside the currently sequenced first part of exon 1 might influence the risk for cARDs.
Except for one subject in the control group, none of the patients in this study was homozygous for 2*(P24T) or *3(L48V). It is of interest to further study subjects who are homozygous for 2* (P24T) or *3(L48V).
In conclusion, our study suggests that it is unlikely that the UGT1A4 genotypes wt/*2(P24T) or wt/*3(L48V) affect the risk of Table 1 The distribution of UGTA14 *2(P24T) and *3 (L48V) variants in subjects with cutaneous adverse reactions from lamotrigine, compared to tolerant controls.
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